Equity

BGF World Healthscience Fund

Overview

Important Information: Capital at Risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested. Investment risk is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political, sustainability-related or regulatory events. The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events. Active management of currency exposure through derivatives may make the Fund more sensitive to changes in foreign exchange rates. If the currency exposures against which the Fund is hedged appreciates investors may not benefit from such appreciation. The Fund seeks to exclude companies engaging in certain activities inconsistent with ESG criteria. Investors should therefore make a personal ethical assessment of the Fund’s ESG screening prior to investing in the Fund. Such ESG screening may adversely affect the value of the Fund’s investments compared to a fund without such screening.

All currency hedged share classes of this fund use derivatives to hedge currency risk. The use of derivatives for a share class could pose a potential risk of contagion (also known as spill-over) to other share classes in the fund. The fund’s management company will ensure appropriate procedures are in place to minimise contagion risk to other share class. Using the drop down box directly below the name of the fund, you can view a list of all share classes in the fund – currency hedged share classes are indicated by the word “Hedged” in the name of the share class. In addition, a full list of all currency hedged share classes is available on request from the fund’s management company

To the extent the Fund undertakes securities lending to reduce costs, the Fund will receive 62.5% of the associated revenue generated and the remaining 37.5% will be received by BlackRock as the securities lending agent. As securities lending revenue sharing does not increase the costs of running the Fund, this has been excluded from the ongoing charges.

Loading

Performance

Performance

Growth of Hypothetical 10,000

Performance chart data not available for display.
View full chart

Distributions

Ex-Date Total Distribution
View full table

  2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Total Return (%) 25.30 14.84 15.05 -4.53 2.98
Constraint Benchmark 1 (%) 23.24 13.52 19.80 -5.41 3.76

Performance is shown after deduction of ongoing charges. Any entry and exit charges are excluded from the calculation.

  1Y 3Y 5Y 10y Incept.
13.69 6.87 10.26 - 10.46
Constraint Benchmark 1 (%) 13.32 7.85 10.33 - 10.11
  YTD 1m 3M 6M 1Y 3Y 5Y 10y Incept.
8.56 2.43 8.56 13.53 13.69 22.05 62.97 - 83.20
Constraint Benchmark 1 (%) 7.47 2.35 7.47 13.78 13.32 25.45 63.48 - 79.66
  From
31-Mar-2019
To
31-Mar-2020
From
31-Mar-2020
To
31-Mar-2021
From
31-Mar-2021
To
31-Mar-2022
From
31-Mar-2022
To
31-Mar-2023
From
31-Mar-2023
To
31-Mar-2024
Total Return (%)

as of Mar 31, 2024

2.78 29.92 10.87 -3.17 13.69
Constraint Benchmark 1 (%)

as of Mar 31, 2024

0.89 29.16 14.94 -3.69 13.32
The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted.

The figures shown relate to past performance. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past

Share Class and Benchmark performance displayed in USD, hedged share class benchmark performance is displayed in USD.

Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: Blackrock

Key Facts

Key Facts

Net Assets of Fund as of Apr 12, 2024 USD 13,604,307,092
Share Class Inception Date Feb 28, 2018
Fund Inception Date Apr 6, 2001
Share Class Currency USD
Base Currency USD
Asset Class Equity
Constraint Benchmark 1 MSCI World Health Care Index
SFDR Classification Article 8
Initial Charge 5.00%
Ongoing Charge 1.03%
ISIN LU1728553774
Annual Management Fee 0.75%
Performance Fee 0.00%
Minimum Initial Investment USD 100000
Minimum Subsequent Investment USD 1000
Use of Income Distributing
Domicile Luxembourg
Regulatory Structure UCITS
Management Company BlackRock (Luxembourg) S.A.
Morningstar Category Sector Equity Healthcare
Dealing Settlement Trade Date + 3 days
Dealing Frequency Daily, forward pricing basis
Bloomberg Ticker BGWHD4U
SEDOL BG0QCX6

Portfolio Characteristics

Portfolio Characteristics

Number of Holdings as of Mar 28, 2024 90
12m Trailing Yield as of Mar 31, 2024 0.19%
Standard Deviation (3y) as of Mar 31, 2024 12.89%
P/E Ratio as of Mar 28, 2024 33.64
P/B Ratio as of Mar 28, 2024 5.25

Sustainability Characteristics

Sustainability Characteristics

Sustainability Characteristics provide investors with specific non-traditional metrics. Alongside other metrics and information, these enable investors to evaluate funds on certain environmental, social and governance characteristics. Sustainability Characteristics do not provide an indication of current or future performance nor do they represent the potential risk and reward profile of a fund. They are provided for transparency and for information purposes only. Sustainability Characteristics should not be considered solely or in isolation, but instead are one type of information that investors may wish to consider when assessing a fund.


The metrics are not indicative of how or whether ESG factors will be integrated into a fund. Unless otherwise stated in fund documentation and included within a fund’s investment objective, the metrics do not change a fund’s investment objective or constrain the fund’s investable universe, and there is no indication that an ESG or Impact focused investment strategy or exclusionary screens will be adopted by a fund. For more information regarding a fund's investment strategy, please see the fund's prospectus.


Review the MSCI methodologies behind Sustainability Characteristics using the links below.

MSCI ESG Fund Rating (AAA-CCC) as of Mar 21, 2024 AA
MSCI ESG % Coverage as of Mar 21, 2024 98.61
MSCI ESG Quality Score (0-10) as of Mar 21, 2024 7.21
MSCI ESG Quality Score - Peer Percentile as of Mar 21, 2024 92.19
Fund Lipper Global Classification as of Mar 21, 2024 Equity Sector Healthcare
Funds in Peer Group as of Mar 21, 2024 525
MSCI Weighted Average Carbon Intensity (Tons CO2E/$M SALES) as of Mar 21, 2024 12.00
MSCI Weighted Average Carbon Intensity % Coverage as of Mar 21, 2024 96.58
All data is from MSCI ESG Fund Ratings as of Mar 21, 2024, based on holdings as of Oct 31, 2023. As such, the fund’s sustainable characteristics may differ from MSCI ESG Fund Ratings from time to time.

To be included in MSCI ESG Fund Ratings, 65% (or 50% for bond funds and money market funds) of the fund’s gross weight must come from securities with ESG coverage by MSCI ESG Research (certain cash positions and other asset types deemed not relevant for ESG analysis by MSCI are removed prior to calculating a fund’s gross weight; the absolute values of short positions are included but treated as uncovered), the fund’s holdings date must be less than one year old, and the fund must have at least ten securities.

Business Involvement

Business Involvement

Business Involvement metrics can help investors gain a more comprehensive view of specific activities in which a fund may be exposed through its investments.


Business Involvement metrics are not indicative of a fund’s investment objective, and, unless otherwise stated in fund documentation and included within a fund’s investment objective, do not change a fund’s investment objective or constrain the fund’s investable universe, and there is no indication that an ESG or Impact focused investment strategy or exclusionary screens will be adopted by a fund. For more information regarding a fund's investment strategy, please see the fund's prospectus.


Review the MSCI methodology behind the Business Involvement metrics, using links below.

MSCI - Controversial Weapons as of Mar 28, 2024 0.00%
MSCI - UN Global Compact Violators as of Mar 28, 2024 0.00%
MSCI - Nuclear Weapons as of Mar 28, 2024 0.00%
MSCI - Thermal Coal as of Mar 28, 2024 0.00%
MSCI - Civilian Firearms as of Mar 28, 2024 0.00%
MSCI - Oil Sands as of Mar 28, 2024 0.00%
MSCI - Tobacco as of Mar 28, 2024 0.00%

Business Involvement Coverage as of Mar 28, 2024 98.89%
Percentage of Fund not covered as of Mar 28, 2024 1.17%
BlackRock business involvement exposures as shown above for Thermal Coal and Oil Sands are calculated and reported for companies that generate more than 5% of revenue from thermal coal or oil sands as defined by MSCI ESG Research. For the exposure to companies that generate any revenue from thermal coal or oil sands (at a 0% revenue threshold), as defined by MSCI ESG Research, it is as follows: Thermal Coal 0.00% and for Oil Sands 0.00%.

Business Involvement metrics are calculated by BlackRock using data from MSCI ESG Research which provides a profile of each company’s specific business involvement. BlackRock leverages this data to provide a summed up view across holdings and translates it to a fund's market value exposure to the listed Business Involvement areas above.


Business Involvement metrics are designed only to identify companies where MSCI has conducted research and identified as having involvement in the covered activity. As a result, it is possible there is additional involvement in these covered activities where MSCI does not have coverage. This information should not be used to produce comprehensive lists of companies without involvement. Business Involvement metrics are only displayed if at least 1% of the fund’s gross weight includes securities covered by MSCI ESG Research.

ESG Integration

ESG Integration

ESG integration is the practice of incorporating financially material environmental, social and governance (ESG) data or information into the investment decision process with the objective of enhancing risk-adjusted returns of our clients’ portfolios. Unless otherwise stated in Fund documentation or included within the Fund's investment objective, inclusion of this statement does not imply that the Fund has an ESG-aligned investment objective or strategy, but rather describes how ESG data or information is considered as part of the overall investment process.

The Fund manager includes ESG considerations in combination with other information in the research and decision phases of the investment process. The Fund manager conducts regular portfolio reviews between with the Risk and Quantitative Analysis group and with the Chief Investment Officers. Where appropriate, these reviews include discussion of the portfolio's exposure to material ESG risks, as well as exposure to sustainability-related business involvements, climate-related metrics, and other factors.

Ratings

Ratings

Morningstar Rating

5 stars
Overall Morningstar Rating for BGF World Healthscience Fund, Class D4, as of Mar 31, 2024 rated against 604 Sector Equity Healthcare Funds.

Morningstar Medalist Rating

Morningstar Medalist Rating - BRONZE
Morningstar has awarded the Fund a Bronze medal. Fewer than 10% of US open-end funds hold medalist ratings. (Effective Nov 9, 2023)

Risk Indicator

Risk Indicator

1
2
3
4
5
6
7
Low Risk High Risk
Low Yield High Yield

Holdings

Holdings

as of Mar 28, 2024
Name Weight (%)
ELI LILLY 7.33
NOVO NORDISK CLASS B 7.11
UNITEDHEALTH GROUP INC 6.66
ABBVIE INC 4.80
MERCK & CO INC 4.52
Name Weight (%)
BOSTON SCIENTIFIC CORP 3.95
AMGEN INC 3.40
ASTRAZENECA PLC 3.28
ABBOTT LABORATORIES 2.97
DANAHER CORP 2.83
Holdings subject to change

Exposure Breakdowns

Exposure Breakdowns

as of Mar 28, 2024

% of Market Value

Type Fund
as of Mar 28, 2024

% of Market Value

Type Fund
as of Mar 28, 2024

% of Market Value

Type Fund
as of Mar 28, 2024

% of Market Value

Type Fund
Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management. Allocations are subject to change.

Pricing & Exchange

Pricing & Exchange

Investor Class Currency NAV NAV Amount Change NAV % Change NAV As Of 52wk High 52wk Low ISIN
D4 USD 17.38 -0.11 -0.63 Apr 12, 2024 18.13 15.21 LU1728553774
Class S2 EUR 10.08 0.03 0.30 Apr 12, 2024 10.36 8.84 LU2624961046
D2 Hgd EUR 12.61 -0.08 -0.63 Apr 12, 2024 13.17 11.14 LU2168656341
B2 USD 9.78 -0.06 -0.61 Apr 12, 2024 10.03 9.78 LU2776654845
A2 EUR 63.51 0.15 0.24 Apr 12, 2024 65.30 55.96 LU0171307068
Class S2 USD 10.72 -0.07 -0.65 Apr 12, 2024 11.18 9.38 LU2624960824
X2 USD 87.06 -0.53 -0.61 Apr 12, 2024 90.78 75.87 LU0462856898
A2 USD 67.58 -0.42 -0.62 Apr 12, 2024 70.52 59.36 LU0122379950
Class S2 Hedged EUR 10.55 -0.06 -0.57 Apr 12, 2024 11.01 9.31 LU2624961129
A4 USD 12.76 -0.08 -0.62 Apr 12, 2024 13.31 11.20 LU2112291526
C2 USD 51.12 -0.32 -0.62 Apr 12, 2024 53.37 45.15 LU0147404148
Class I4 USD 11.90 -0.08 -0.67 Apr 12, 2024 12.42 10.41 LU2297183803
A2 Hgd JPY 1,313.00 -8.00 -0.61 Apr 12, 2024 1,374.00 1,184.00 LU1948809360
I2 USD 15.82 -0.10 -0.63 Apr 12, 2024 16.50 13.84 LU1960219225
Class AI2 EUR 16.91 0.04 0.24 Apr 12, 2024 17.38 14.90 LU1960224654
A2 Hgd CNH 190.07 -1.19 -0.62 Apr 12, 2024 198.65 169.23 LU1254117382
D2 USD 76.52 -0.46 -0.60 Apr 12, 2024 79.81 66.98 LU0329593007
E2 USD 60.32 -0.36 -0.59 Apr 12, 2024 62.95 53.09 LU0122380701
A4 EUR 11.99 0.03 0.25 Apr 12, 2024 12.33 10.56 LU2112291799
A2 Hgd HKD 227.02 -1.41 -0.62 Apr 12, 2024 237.04 200.22 LU1061106388
E2 EUR 56.68 0.13 0.23 Apr 12, 2024 58.29 50.06 LU0171309270
I2 Hgd EUR 12.73 -0.08 -0.62 Apr 12, 2024 13.29 11.23 LU2178160680
I2 EUR 14.87 0.04 0.27 Apr 12, 2024 15.28 13.04 LU1960219571
A2 Hgd SGD 22.35 -0.13 -0.58 Apr 12, 2024 23.35 19.80 LU1057294990
Class A10 USD 10.15 -0.06 -0.59 Apr 12, 2024 10.65 9.21 LU2533724352
D2 EUR 71.91 0.17 0.24 Apr 12, 2024 73.90 63.14 LU0827889485
A2 Hgd AUD 21.77 -0.13 -0.59 Apr 12, 2024 22.74 19.27 LU1023059063
Class X10 USD 10.40 -0.06 -0.57 Apr 12, 2024 10.88 9.31 LU2471418801
D5 GBP 14.22 0.03 0.21 Apr 12, 2024 14.61 12.61 LU2112292763
I2 JPY 2,420.00 -18.00 -0.74 Apr 12, 2024 2,496.00 1,974.00 LU2263536315
C2 EUR 48.04 0.11 0.23 Apr 12, 2024 49.42 42.57 LU0331289677
A2 Hgd EUR 14.50 -0.09 -0.62 Apr 12, 2024 15.14 12.85 LU1822774284
E2 Hgd EUR 10.61 -0.07 -0.66 Apr 12, 2024 11.09 9.43 LU2298322558

Portfolio Managers

Portfolio Managers

Erin Xie, PhD
Head of the Fundamental Equities Health Sciences Team, Portfolio Manager, Managing Director

Erin Xie, PhD, Managing Director, is head of the Health Sciences team within BlackRock Fundamental Equities and lead portfolio manager for the Health Sciences equity portfolios.

Xiang Liu
Xiang Liu

Literature

Literature